KABI PHARMACIA/ADRIA's FRAGMIN (DALTEPARIN) IS "APPROVABLE"
Executive Summary
KABI PHARMACIA/ADRIA's FRAGMIN (DALTEPARIN) IS "APPROVABLE" at FDA Jan. 10 for the prevention of deep vein thrombosis in patients undergoing abdominal surgery who are considered to be at risk of thromboembolic complications. The low molecular weight heparin is already marketed in Japan and Europe.